An Assessment of Statin Safety by Hepatologists

Overview

Journal Am J Cardiol

Specialty Cardiology & Vascular Diseases

Date 2006 Apr 4

PMID 16581333

Citations 96

Authors

David E Cohen

Frank A Anania

Naga Chalasani

Affiliations

Soon will be listed here.

Abstract

The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association's (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.

Citing Articles

Deranged Liver Function Tests Associated With Hyperferritinemia in a Patient With Type 2 Diabetes Mellitus: A Case Study and Literature Review.

Elmakki E Cureus. 2024; 16(8):e66074.

PMID: 39229407 PMC: 11368582. DOI: 10.7759/cureus.66074.

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?.

Xiao Y, Ba Z, Pang S, Liu D, Wang H, Liang H Rev Cardiovasc Med. 2024; 23(11):380.

PMID: 39076187 PMC: 11269069. DOI: 10.31083/j.rcm2311380.

A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.

Zhang S, Ren X, Zhang B, Lan T, Liu B Molecules. 2024; 29(8).

PMID: 38675679 PMC: 11052408. DOI: 10.3390/molecules29081859.

Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update.

Mao Y, Ma S, Liu C, Liu X, Su M, Li D Hepatol Int. 2024; 18(2):384-419.

PMID: 38402364 DOI: 10.1007/s12072-023-10633-7.

Lipid-Lowering Efficacy of Combination Therapy With Moderate-Intensity Statin and Ezetimibe Versus High-Intensity Statin Monotherapy: A Randomized, Open-Label, Non-Inferiority Trial From Korea.

Choi H, Kang S, Jeong S, Yoon C, Youn T, Song W J Lipid Atheroscler. 2023; 12(3):277-289.

PMID: 37800112 PMC: 10548190. DOI: 10.12997/jla.2023.12.3.277.